|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STXBP6 |
Gene summary for STXBP6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STXBP6 | Gene ID | 29091 |
| Gene name | syntaxin binding protein 6 | |
| Gene Alias | HSPC156 | |
| Cytomap | 14q12 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8NFX7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29091 | STXBP6 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.01e-03 | -3.40e-01 | 0.0155 |
| 29091 | STXBP6 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.82e-04 | -5.75e-01 | -0.1207 |
| 29091 | STXBP6 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.81e-04 | -7.40e-01 | -0.2061 |
| 29091 | STXBP6 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.57e-08 | -4.26e-01 | 0.3859 |
| 29091 | STXBP6 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.07e-14 | -5.20e-01 | 0.3005 |
| 29091 | STXBP6 | A002-C-010 | Human | Colorectum | FAP | 1.74e-03 | 2.69e-01 | 0.242 |
| 29091 | STXBP6 | A001-C-207 | Human | Colorectum | FAP | 2.52e-02 | 2.74e-01 | 0.1278 |
| 29091 | STXBP6 | A015-C-203 | Human | Colorectum | FAP | 1.25e-28 | -5.72e-01 | -0.1294 |
| 29091 | STXBP6 | A015-C-204 | Human | Colorectum | FAP | 2.45e-03 | -2.55e-01 | -0.0228 |
| 29091 | STXBP6 | A014-C-040 | Human | Colorectum | FAP | 3.24e-03 | -3.21e-01 | -0.1184 |
| 29091 | STXBP6 | A002-C-201 | Human | Colorectum | FAP | 2.88e-09 | -3.61e-01 | 0.0324 |
| 29091 | STXBP6 | A002-C-203 | Human | Colorectum | FAP | 1.59e-05 | 3.47e-01 | 0.2786 |
| 29091 | STXBP6 | A001-C-119 | Human | Colorectum | FAP | 1.29e-11 | -5.91e-01 | -0.1557 |
| 29091 | STXBP6 | A001-C-108 | Human | Colorectum | FAP | 5.37e-11 | -3.13e-01 | -0.0272 |
| 29091 | STXBP6 | A002-C-205 | Human | Colorectum | FAP | 2.88e-22 | -5.73e-01 | -0.1236 |
| 29091 | STXBP6 | A015-C-006 | Human | Colorectum | FAP | 1.07e-15 | -5.87e-01 | -0.0994 |
| 29091 | STXBP6 | A015-C-106 | Human | Colorectum | FAP | 2.71e-09 | -1.20e-01 | -0.0511 |
| 29091 | STXBP6 | A002-C-114 | Human | Colorectum | FAP | 1.07e-16 | -4.95e-01 | -0.1561 |
| 29091 | STXBP6 | A015-C-104 | Human | Colorectum | FAP | 3.83e-27 | -5.40e-01 | -0.1899 |
| 29091 | STXBP6 | A001-C-014 | Human | Colorectum | FAP | 1.99e-09 | -2.22e-01 | 0.0135 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004325426 | Oral cavity | EOLP | regulation of protein-containing complex assembly | 112/2218 | 428/18723 | 1.58e-16 | 1.35e-13 | 112 |
| GO:004819322 | Oral cavity | EOLP | Golgi vesicle transport | 72/2218 | 296/18723 | 1.43e-09 | 9.55e-08 | 72 |
| GO:000689222 | Oral cavity | EOLP | post-Golgi vesicle-mediated transport | 35/2218 | 104/18723 | 4.30e-09 | 2.43e-07 | 35 |
| GO:001605022 | Oral cavity | EOLP | vesicle organization | 65/2218 | 300/18723 | 8.62e-07 | 2.15e-05 | 65 |
| GO:000689322 | Oral cavity | EOLP | Golgi to plasma membrane transport | 20/2218 | 60/18723 | 1.03e-05 | 1.84e-04 | 20 |
| GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
| GO:00068874 | Oral cavity | EOLP | exocytosis | 60/2218 | 352/18723 | 2.32e-03 | 1.43e-02 | 60 |
| GO:009887622 | Oral cavity | EOLP | vesicle-mediated transport to the plasma membrane | 27/2218 | 136/18723 | 4.73e-03 | 2.54e-02 | 27 |
| GO:00610252 | Oral cavity | EOLP | membrane fusion | 31/2218 | 163/18723 | 5.09e-03 | 2.67e-02 | 31 |
| GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
| GO:001605017 | Thyroid | PTC | vesicle organization | 163/5968 | 300/18723 | 4.74e-16 | 3.69e-14 | 163 |
| GO:0043254113 | Thyroid | PTC | regulation of protein-containing complex assembly | 215/5968 | 428/18723 | 1.23e-15 | 9.09e-14 | 215 |
| GO:000689218 | Thyroid | PTC | post-Golgi vesicle-mediated transport | 66/5968 | 104/18723 | 3.36e-11 | 1.24e-09 | 66 |
| GO:000689317 | Thyroid | PTC | Golgi to plasma membrane transport | 41/5968 | 60/18723 | 7.26e-09 | 1.82e-07 | 41 |
| GO:009887618 | Thyroid | PTC | vesicle-mediated transport to the plasma membrane | 74/5968 | 136/18723 | 4.20e-08 | 9.08e-07 | 74 |
| GO:00482846 | Thyroid | PTC | organelle fusion | 71/5968 | 141/18723 | 3.68e-06 | 4.70e-05 | 71 |
| GO:00610256 | Thyroid | PTC | membrane fusion | 77/5968 | 163/18723 | 2.86e-05 | 2.78e-04 | 77 |
| GO:00069065 | Thyroid | PTC | vesicle fusion | 54/5968 | 106/18723 | 3.39e-05 | 3.21e-04 | 54 |
| GO:00901745 | Thyroid | PTC | organelle membrane fusion | 55/5968 | 110/18723 | 5.64e-05 | 4.99e-04 | 55 |
| GO:00510518 | Thyroid | PTC | negative regulation of transport | 176/5968 | 470/18723 | 5.44e-03 | 2.49e-02 | 176 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STXBP6 | SNV | Missense_Mutation | c.501N>C | p.Gln167His | p.Q167H | Q8NFX7 | protein_coding | tolerated(0.05) | benign(0.044) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| STXBP6 | SNV | Missense_Mutation | novel | c.49N>A | p.Glu17Lys | p.E17K | Q8NFX7 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| STXBP6 | SNV | Missense_Mutation | rs767031935 | c.48N>A | p.Asp16Glu | p.D16E | Q8NFX7 | protein_coding | tolerated(0.13) | probably_damaging(0.981) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| STXBP6 | SNV | Missense_Mutation | novel | c.618N>A | p.Met206Ile | p.M206I | Q8NFX7 | protein_coding | tolerated(0.25) | benign(0) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| STXBP6 | SNV | Missense_Mutation | c.233N>T | p.Ser78Leu | p.S78L | Q8NFX7 | protein_coding | deleterious(0.03) | benign(0.131) | TCGA-C5-A1MN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| STXBP6 | SNV | Missense_Mutation | rs769103083 | c.526N>T | p.Arg176Cys | p.R176C | Q8NFX7 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| STXBP6 | SNV | Missense_Mutation | novel | c.226C>T | p.Arg76Trp | p.R76W | Q8NFX7 | protein_coding | deleterious(0) | possibly_damaging(0.646) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| STXBP6 | SNV | Missense_Mutation | c.274G>A | p.Asp92Asn | p.D92N | Q8NFX7 | protein_coding | tolerated(0.26) | benign(0) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| STXBP6 | SNV | Missense_Mutation | c.34N>A | p.Phe12Ile | p.F12I | Q8NFX7 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| STXBP6 | SNV | Missense_Mutation | novel | c.406N>A | p.Asp136Asn | p.D136N | Q8NFX7 | protein_coding | tolerated(0.27) | benign(0.01) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |